Avidity Biosciences Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 14, 2021 / 08:40PM GMT
Unidentified Analyst -

Good afternoon, everyone, and thank you for joining us. My name is [Caitlin], and I'm a member of the healthcare investment banking team here at JPMorgan. It's our great pleasure to have Avidity presenting here today. (Operator Instructions)

And with that, I'd like to introduce Sarah Boyce, President and CEO of Avidity. Sarah?

Sarah Boyce - Avidity Biosciences, Inc. - President, CEO & Director

Thanks very much, [Cat], and thank you to the JPMorgan team for inviting us to present at your annual meeting. 2020 was an incredible year for Avidity as a company. We advanced our Antibody Oligonucleotide Conjugate technology, and we also became a public company, and I'm very thankful for the team that made that happen.

Moving into 2021, I'm really excited and looking forward to being able to move and bring the first of a new class of RNA therapeutics into the clinic. During the course of this presentation, I will be making forward-looking statements.

Moving to Slide 3. Our mission as a company is to improve the lives of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot